A novel long non-coding RNA PCLN16 facilitates androgen receptor signaling in prostate cancer.

Biochem Biophys Res Commun

Department of Pharmacy, Xinjiang Medical University, Urumqi 830011, Xinjiang, PR China. Electronic address:

Published: January 2021

The prostate cancer (PCa) poses serious threat to men's health. The androgen receptor (AR) is essential for normal prostate development and prostate cancer progression. We identified a novel lncRNA PCLN16 which is significantly correlated with AR signaling during prostate cancer progression. The AR-regulated PCLN16 was abundantly overexpressed in localized or metastatic prostate cancer tissues and AR-dependent cell lines. PCLN16 silence suppressed AR signaling and tumor growth. PCLN16 interacted with Huntingtin interacting protein 1 (HIP1) transcript to reduce HIP1 degradation. Therefore, PCLN16 could augment AR signaling via a novel positive feedback loop. Our experiments support an oncogenic role for PCLN16 and suggest that PCLN16 might serve as a potential target for therapeutic intervention.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbrc.2020.12.043DOI Listing

Publication Analysis

Top Keywords

prostate cancer
20
pcln16
8
androgen receptor
8
signaling prostate
8
cancer progression
8
prostate
6
cancer
5
novel long
4
long non-coding
4
non-coding rna
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!